CYTK

Cytokinetics, IncorporatedNASDAQHealthcare

$66.73+0.18%ClosedMarket Cap: $8.22B

As of 2026-04-06

Recent Analyst Ratings

Date	Firm	Action	Rating	Previous
2026-03-18	Mizuho	—	Outperform	—
2026-03-17	JP Morgan	—	Overweight	—
2026-03-06	UBS	—	Neutral	—
2026-02-26	Leerink Partners	—	Outperform	—
2026-02-25	Citizens	—	Market Outperform	—
2026-02-25	Needham	—	Buy	—
2026-02-20	RBC Capital	—	Outperform	—
2026-02-03	Truist Securities	—	Buy	—
2026-01-21	B. Riley Securities	—	Buy	—
2026-01-20	JP Morgan	—	Overweight	—

Forward Estimates

Period	EPS Est.	Revenue Est.	# Analysts
Fri Dec 31	$-4.78	$372.3M	13
Sun Dec 31	$-2.12	$843.5M	14
Mon Dec 31	$0.86	$1.45B	8
Tue Dec 31	$4.25	$2.21B	12